https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52963 Wed 28 Feb 2024 16:09:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55001 Wed 27 Mar 2024 16:38:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48900 Wed 19 Apr 2023 16:40:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47116 Wed 14 Dec 2022 12:11:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34579 Wed 09 Mar 2022 16:00:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54632 Wed 06 Mar 2024 10:59:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48767 Wed 05 Apr 2023 13:55:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52094 Thu 28 Sep 2023 14:28:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45363 Thu 27 Oct 2022 11:46:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31414 6-methylguanine adduct. This activates the mismatch repair (MMR) process inducing apoptosis and mutagenesis. This review describes key juxtaposed drivers in the balance between alkylation induced mutagenesis and apoptosis. Mutations in MMR genes are the probable drivers for alkylation based drug resistance. Critical to this interaction are the dose-response and temporal interactions between adduct formation and MMR mutations. The precision in dose interval, dose-responses and temporal relationships dictate a role for alkylating agents in either promoting experimental tumour formation or inducing tumour cell death with chemotherapy. Importantly, this resultant loss of chemotherapeutic selective pressure provides opportunity to explore novel therapeutics and appropriate combinations to minimise alkylation based drug resistance and tumour relapse.]]> Thu 17 Feb 2022 09:26:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54816 Thu 14 Mar 2024 14:38:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28464 Sat 24 Mar 2018 07:39:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27417 Sat 24 Mar 2018 07:35:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30292 Sat 24 Mar 2018 07:33:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24125 Sat 24 Mar 2018 07:11:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40395 TP53 SNPs in exon 4 and intron 4 on cancer risk, clinicopathological features and expression of TP53 isoforms. The intron 4 SNPs were significantly over-represented in cohorts of mixed cancers compared to three ethnically matched controls, suggesting they confer increased cancer risk. Further analysis showed that heterozygosity at rs1042522(GC) and either of the two intronic SNPs rs9895829(TC) and rs2909430(AG) confer a 2.34-5.35-fold greater risk of developing cancer. These SNP combinations were found to be associated with shorter patient survival for glioblastoma and prostate cancer. Additionally, these SNPs were associated with tumor-promoting inflammation as evidenced by high levels of infiltrating immune cells and expression of the Δ133TP53 and TP53ß transcripts. We propose that these SNP combinations allow increased expression of the Δ133p53 isoforms to promote the recruitment of immune cells that create an immunosuppressive environment leading to cancer progression.]]> Mon 25 Jul 2022 09:15:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26160 Mon 22 Jul 2019 13:58:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44180 Mon 10 Oct 2022 10:34:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51948 Fri 22 Sep 2023 17:06:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39977 Fri 22 Jul 2022 11:56:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51740 Fri 15 Sep 2023 18:14:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51543 Fri 08 Sep 2023 14:59:23 AEST ]]>